// Biotech and Pharma Therapeutics
Texas measles outbreak marks first fatality as more cases reported
February 26, 2025 / Measles Outbreak / Texas / Unvaccinated Child Measles / Measles Prevention
A Texas child has died from measles, marking the first U.S. measles-related fatality since 2015. The unvaccinated child was hospitalized in Lubbock amid a growing outbreak, with 18 others also hospitalized.
Eli Lilly unveils plan for four U.S. “mega-sites”
February 26, 2025 / Eli Lilly / Manufacturing / GLP-1 Drug Production / Injectable Therapy Manufacturing
Eli Lilly plans to open four U.S. “”mega-sites”” to reshore pharmaceutical manufacturing, reducing reliance on overseas suppliers. These sites will produce active pharmaceutical ingredients and expand injectable therapy production, creating 3,000 jobs and reinforcing domestic drug supply chains.
Swarm deal focuses on clinical and commercial supply of T-cell therapies
February 25, 2025 / T-cell Therpay Supply / Swarm Oncology Partnership / Solid Tumor Immunotherapy / Cellex Cell Professionals / Advanced Cancer Treatment
Swarm Oncology partnered with Cellex Cell Professionals to enhance clinical and commercial T-cell therapy supply. The collaboration aims to advance immunotherapy, addressing challenges in treating advanced solid cancers and achieving long-term remission.
Kiniksa slims focus to cardiovascular diseases
February 26, 2025 / Kiniksa Pharmaceuticals / Arcalyst Revenue Growth / Pericarditis Treatment / Cardiovascular Drug Pipeline / FDA Approval
Kiniksa Pharmaceuticals is narrowing its focus to cardiovascular diseases, driven by strong growth of Arcalyst (rilonacept), its FDA-approved therapy for recurrent pericarditis. Arcalyst generated $417 million in 2024, with projected 2025 revenue of up to $580 million.
The New Reality of Hospital-Payer Contracts: How Baptist Health Negotiated with Florida Blue
February 25, 2024 / Hospital-payer Negotiations / Baptist Health Florida Blue / Reimbursement Rates / Value-based Care Contracts / Insurance Claim Denials
Baptist Health successfully negotiated a complex contract with Florida Blue, highlighting shifting hospital-payer dynamics. The eight-month process required financial analysis, external consultants, and board involvement, ultimately securing better reimbursement rates and value-based care initiatives.
// 4th Industrial Revolution
Radiopharmaceutical Manufacturing: A High-Stakes Race Against Time
February 26, 2025 / Radiopharmaceutical Manufacturing / Radioactive Drug Logistics / Cancer Therapy / Supply Chain
Radiopharmaceutical manufacturing faces unique challenges due to the perishability of radioactive isotopes, complex logistics, and specialized infrastructure. Reliable production and delivery are critical, requiring early investment in supply chain resilience to ensure life-saving therapies reach patients on time.
Countering telehealth abuse with hybrid model
February 25, 2025 / Hybrid Telehealth Model / Singapre Telemedicine Regulations / Obesity Treatment Telehealth / Weight Management Services / Telehealth Data Security
Singapore is tightening regulations on telemedicine, prompting ORA to launch a hybrid weight management service combining virtual and in-person care. This model aims to enhance care quality, ensure responsible obesity treatment, and establish telehealth standards while prioritizing data security.
Machine learning vs. bodily pain: 5 points of promise and challenge
February 25, 2025 / Machine Learning Pain Assessment / AI in Pain Management / Automated Pain Detection / Wearable Pain Monitoring / Transfer Learning Healthcare
Machine learning (ML) shows promise in automated pain assessment through real-time monitoring, wearable tech, and transfer learning. Challenges include data bias, small sample sizes, and deep learning limitations. Further research and interdisciplinary collaboration are needed for clinical integration.
SingHealth doubles down on AI integration
February 25, 2025 / SingHealth AI Integration / AI in Healthcare / Singapore / Smart ICU Monitoring / Digital Imaging AI / Clinical Analytics
SingHealth is expanding AI integration through a partnership with Philips, focusing on digital imaging, real-time data analytics, and smart ICU monitoring. These initiatives align with Singapore’s broader push for AI-driven, patient-centric healthcare transformation.
Lack of AI governance poses threat to data security, new HIMSS research shows
February 25, 2025 / AI Governance Healthcare / Cybersecurity Trends / HIMSS Cybersecurity Report / AI Security Risks / Ransomeware Healthcare Threats
HIMSS research highlights the need for stronger AI governance in healthcare cybersecurity. While IT security investments are rising, gaps in AI oversight and workforce retention pose risks. Enhanced policies, education, and monitoring are essential to mitigate emerging cyber threats.
// Business & Markets
Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing
February 26, 2025 / Eikon Therapeutics / Funding / Melanoma Immunotherapy / PARP1 Inhibitor Cancer / Oncology Drug Development
Eikon Therapeutics raised $350.7M to advance its oncology pipeline, led by EIK1001, a TLR7/8 agonist in Phase 3 melanoma trials. Additional candidates include PARP1-selective inhibitors for solid tumors and brain cancers, with expansion into DNA repair-targeted therapies.
Quest to buy Fresenius Medical Care kidney testing assets
February 23, 2025 / Quest Diagnostics Acquisition / Kidney Testing / Renal Disease Diagnostics / Spectra Laboratories
Quest Diagnostics is acquiring Fresenius Medical Care’s kidney disease lab testing assets, including dialysis-related water testing, to enhance its renal diagnostics portfolio. The deal aims to improve efficiency, reduce test turnaround times, and optimize Quest’s lab operations.
Thermo Fisher to buy Solventum’s purification and filtration unit for $4.1B
February 25, 2025 / Thermo Fisher Acquisition / Solventum Filtration Unit / Biologics Manufacturing / Purification Technology
Thermo Fisher is acquiring Solventum’s purification and filtration unit for $4.1B to expand its bioprocessing capabilities. The acquisition enhances Thermo Fisher’s biologics manufacturing portfolio, boosting filtration expertise and positioning it against industry leaders like Danaher and Repligen.
Idorsia cuts development costs in updated Viatris deal
February 26, 2025 / Idorsia Vistris Deal / Selatogrel Development / Cenerimod Clinical Trials / Biotech Cost Reduction / Pharmaceutical Milestone Payments
Idorsia has renegotiated its deal with Viatris, cutting its development commitment for selatogrel and cenerimod from $200M to $100M in exchange for a $250M reduction in future milestone payments, easing short-term financial pressure.
Repare Therapeutics to cut 75% of workforce in major restructuring
February 26, 2025 / Repare Therapeutics Layoffs / Oncology Drug Development / Roche Collaboration
Repare Therapeutics is cutting 75% of its workforce to extend cash reserves through 2027, following Roche’s termination of their camonsertib collaboration. The company will focus on early-stage oncology programs targeting PLK4 and Polθ ATPase.
// Legal & Regulatory
Google receives FDA clearance for loss of pulse detection technology
February 26, 2025 / Google FDA Clearance / Loss of Pulse Detection / Pixel Watch / 3 Health Features / AI Emergency Alert / Wearable Health Techonology
Google has received FDA clearance for its loss of pulse detection technology on the Pixel Watch 3, which uses AI and sensors to confirm pulse loss and automatically alert emergency services. The feature will launch in the U.S. by March 2025.
Odronextamab BLA resubmission accepted for FDA review
February 26, 2025 / Odronextamab FDA Review / Follicular Lymphoma Treatment / Regeneron BLA Resubmission / OLYMPIA-1 Clinical Trial
The FDA has accepted Regeneron’s BLA resubmission for odronextamab in relapsed/refractory follicular lymphoma, with a decision expected by July 30, 2025. The filing follows enrollment completion in the Phase III OLYMPIA-1 trial, addressing prior regulatory concerns.
Merck expects oncology king Keytruda to face IRA ‘price setting’ process starting in 2026
February 26, 2025 / Keytruda IRA Price Negotiations / Merck Patent Expiration / Medicare Drug Pricing / Oncology Market Impact
Merck anticipates Keytruda will face Inflation Reduction Act (IRA) price negotiations in 2026, with lower Medicare pricing effective in 2028, coinciding with its U.S. patent expiration. The company is pursuing litigation against the IRA while preparing for biosimilar competition.
All smiles at GRIN over radiprodil prospects
February 26, 2025 / Radiprodil FDA Breakthrough / NMDA Receptor Modulator / Pediatric Seizure Therapy
The FDA has granted Breakthrough Therapy designation to radiprodil, GRIN Therapeutics’ investigational NMDA receptor modulator, for treating seizures in GRIN-related neurodevelopmental disorder with gain-of-function mutations, based on positive Phase Ib Honeycomb study data.
FDA accepts Teva and Medincell’s Uzedy sNDA
February 26, 2025 / Uzedy sNDA FDA / Bipolar Treatment / Teva Medincell Collaboration
The FDA has accepted Teva and Medincell’s sNDA for Uzedy (risperidone) as a long-acting injectable (LAI) maintenance treatment for bipolar I disorder. If approved, it would expand treatment options for over 3.4 million U.S. patients.
// Research & Development
Microbiotica unveils new data on MB097 at AACR IO meeting
February 26, 2025 / MB097 Microbiome Therapy / KEYTRUDA Combination Treatment / Gut Bacteria Immune Response
Microbiotica presented new preclinical data on MB097, an oral microbiome therapy in development with KEYTRUDA for advanced melanoma. Findings suggest MB097 enhances immune response by activating cytotoxic T lymphocytes and modulating tumor-associated macrophages. Phase 1b results are expected in 2025.
AstraZeneca therapy improves survival in late-stage breast cancer trial
February 25, 2025 / Camizestrant Breast Cancer / AstraZeneca Oncology / Advanced Breast Cancer Therapy
AstraZeneca’s camizestrant improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer in the SERENA-6 trial. Used first-line with a standard-of-care agent, the treatment targets genetic mutations that drive tumor growth.
Alligator Bioscience soars on positive mitazalimab trial
February 26, 2025 / Mitazalimab Pancreatic Cancer / Alligator Bioscience / Immunotherapy / Cancer Treatment
Alligator Bioscience’s mitazalimab showed a 29.4% 24-month survival rate in metastatic pancreatic cancer when combined with mFOLFIRINOX in the Phase II OPTIMIZE-1 trial, significantly outperforming standard chemotherapy, reinforcing its breakthrough immunotherapy potential.
Candel reports extended survival in Phase II CAN-2409 trial
February 26, 2025 / CAN-2409 Pancreatic Cancer / Candel Therapeutics Trial / PDAC Immunotherapy / Cancer Survival / Valtrex Combination Therapy
Candel Therapeutics’ CAN-2409 demonstrated a 31.4-month median overall survival in non-metastatic pancreatic ductal adenocarcinoma (PDAC), more than doubling survival compared to standard treatment. The Phase II trial combined CAN-2409 with GSK’s Valtrex and chemoradiation therapy.
Emalex dopamine blocker stops Tourette syndrome relapse in phase 3 win
February 25, 2025 / Ecopipam Tourette Treatment / Emalex Phase 3 Trial / Dopamine Blocker for Tics / FDA Approval
Emalex Biosciences’ ecopipam, a D1 dopamine receptor blocker, significantly reduced Tourette syndrome relapse in a Phase 3 trial. The drug will be submitted for FDA approval in 2025 as a potential first-in-class treatment for vocal and motor tics.
// Politics
Tough path for pill penalty fix
February 25, 2025 / EPIC Act HR 1492 / IRA Pill Penalty / Small Molecule Drug Investment / Medicare Price Negotiation / Innovation Policy
The EPIC Act (H.R. 1492) aims to extend Medicare price negotiation exemption for small molecule drugs from 9 to 13 years, aligning with biologics. This change seeks to counter the IRA’s “pill penalty”, which discourages small molecule drug investment.
CDC will no longer process transgender data
February 25, 2025 / CDC Transgender Data Policy / Trump Executive Order Health / Public Health Data Changes
The CDC will stop processing transgender identity data to comply with President Trump’s executive order, impacting federal health surveillance systems. This move may hinder research on transgender health disparities and public health initiatives.
DOGE for Ohio? Vivek Ramaswamy enters governor’s race pushing cuts and merit pay
February 23, 2025 / Vivek Ramaswamy / Ohio / Biotech Entrepreneur Politics / DOGE Governement Efficiency / Merit-based Teacher Pay
This article focuses on Vivek Ramaswamy’s bid for Ohio governor, highlighting his proposals to cut regulations, reshape education, and phase out income tax. His biotech background and ties to Trump’s cost-cutting DOGE initiative shape his campaign narrative.
PhRMA leaders prepare to meet with Trump as new chair Albert Bourla espouses optimism
February 20, 2025 / PhRMA Trump Meeting / IRA Drug Pricing Reforms / Albert Bourla Pfizer
PhRMA leaders, led by new chair Albert Bourla, will meet with President Trump to advocate for IRA drug pricing reforms, stronger intellectual property protections, and FDA modernization. The industry faces uncertainty under HHS Secretary RFK Jr., given his past anti-vaccine views.
In FDA job cuts, experts see threat of far-reaching impact
February 20, 2025 / FDA Job Cuts / Trump Administration / Healthcare Policy / Drug Regulation Impact / Biomedical Research Funding / Public Health Workforce Reduction
The FDA, CDC, and NIH face major staff cuts under the Trump administration’s cost-reduction plan, potentially weakening drug regulation, disease surveillance, and biomedical research. Experts warn these layoffs could disrupt public health and drug approval processes long-term.